Protocol Ledger

NCT04817618 · Phase III · RECRUITING

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Interventional Phase III clinical trial protocol NCT04817618 sponsored by Novartis in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-28 Enrollment: 98 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04817618
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)98 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04817618
Protocol FieldVerified Registry Value
NCT IdentifierNCT04817618
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment98 participants (ESTIMATED)
Registered Start Date2021-07-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04817618
Hospital Research SiteLocationSite Profile
Johns Hopkins Hospital and Kimmel Cancer CenterBaltimore, MDOpen Hospital Dossier ->
Brigham and Women's HospitalBoston, MAOpen Hospital Dossier ->
Albany Medical CenterAlbany, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI